Avid Radiopharmaceuticals
Robert Morrison has a diverse work experience in the pharmaceutical and biotechnology industry. Robert has held various director-level positions, including Senior Director of Business Development at Avid Radiopharmaceuticals, Head of US R&D Licensing at Galderma, Director of New Projects at CollaGenex Pharmaceuticals, Vice President of Strategic Business Development at BTG International, Director of Global Biotechnology Development at BASF Corporation, and Director of Global Biotechnology Development at American Cyanamid. Earlier in their career, they served as the Director of Product Development at DNA Plant Technology, where they were responsible for conceptualizing, inventing, and developing unique vegetable and high-value products.
Robert Morrison has a Ph.D. in Genetics & Physiology from Rutgers University. Robert also has a Bachelor of Science degree in the Biology Department from The College of New Jersey (formerly Trenton State College).
This person is not in any offices
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.